Category: Anticoagulant

COVID-19 vaccines and thrombosis with thrombocytopenia syndrome

Posted on | Posted on jmurphy | Leave a Comment on COVID-19 vaccines and thrombosis with thrombocytopenia syndrome

Authors: Chih-Cheng Lai 1, Wen-Chien Ko 2, Chih-Jung Chen 3, Po-Yen Chen 4, Yhu-Chering Huang 3, Ping-Ing Lee 5, Po-Ren Hsueh 6 7 Abstract Introduction: To combat COVID-19, scientists all over the world have expedited the process of vaccine development. Although interim analyses of clinical trials have demonstrated the efficacy and safety of COVID-19 vaccines, a serious but rare adverse event, thrombosis with thrombocytopenia syndrome (TTS), has been reported following […]

Anticoagulation in COVID-19: current concepts and controversies

Posted on | Posted on jmurphy | Leave a Comment on Anticoagulation in COVID-19: current concepts and controversies

Authors: http://orcid.org/0000-0002-3809-8926Atanu Chandra1, 6289Uddalak Chakraborty2, Shrestha Ghosh1, Sugata Dasgupta3 Abstract Rising incidence of thromboembolism secondary to COVID-19 has become a global concern, with several surveys reporting increased mortality rates. Thrombogenic potential of the SARS-CoV-2 virus has been hypothesised to originate from its ability to produce an exaggerated inflammatory response leading to endothelial dysfunction. Anticoagulants have remained the primary […]

Better Anticoagulated Than Not! Hypercoagulability in COVID-19

Posted on | Posted on jmurphy | Leave a Comment on Better Anticoagulated Than Not! Hypercoagulability in COVID-19

Authors: Dhauna P. Karam, MD1 Incidence of thrombotic complications in patients with COVID-19 who are critically ill is high, with an estimated incidence of 31% for arterial or venous thromboembolism (VTE), acute pulmonary embolism, ischemic stroke, and myocardial infarction. On the basis of the study by Klok et al,1 pulmonary embolism was the most common thrombotic […]